Population‐Level Real‐World Healthcare Costs in Men and Women With Haemophilia A

INTRODUCTION: Even with modern prophylaxis options, people living with haemophilia have significantly lower quality of life and joint health outcomes than those without. AIM: Our goal was to determine if real-world health-system costs are higher for people living with haemophilia A compared to those without and determine how joint-health state impacts this cost. METHODS: We utilized a population-level, retrospective study design using health administrative data to determine the impact of sex and joint-health states on cross-sectional cost. Cases were identified using diagnostic codes. Joint health states were determined in 30-day intervals by stepping forward and backward from joint replacement surgeries. Control groups were established through propensity score matching, aligning participants based on demographic, economic and health-related variables. Direct 30-day medical costs were generated in 2022 CAD. The impact of sex and disease health phases on direct healthcare system costs was analyzed through a two-part regression model. RESULTS: 2341 eligible individuals with haemophilia A were identified. 26% were female. In pre-severe joint damage, mean 30-day costs were higher for patients with haemophilia A-$910 (standard deviation SD: $4069) for females and $724 (SD: $3577) for males, compared to $469 (±$2126) and $352 (±$2188) for matched controls, respectively. The regression model showed that current joint health state, number of other comorbidities, haemophilia status and sex were important factors within healthcare system cost. CONCLUSIONS: The results of this study indicate that even with haemophilia treatment there remains an increased healthcare system cost for those with haemophilia A, regardless of sex.